Telomir Pharmaceuticals Common StockNASDAQ: TELO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

09 April 2019

Next earnings report:

29 November 2024

Last dividends:

N/A

Next dividends:

N/A
$130.28 M
-63%vs. 3y high
48%vs. sector
-vs. 3y high
-vs. sector
294.69
-43%vs. 3y high
100%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 23:13:09 GMT
$4.40+$0.04(+0.92%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

TELO Latest News

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
accesswire.com21 November 2024 Sentiment: -

MIAMI, FL / ACCESSWIRE / November 21, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced groundbreaking preclinical results confirming the efficacy of Telomir-1, a compound designed to effectively turn back the biological clock and support longevity. Using advanced in vivo microfluidic technology, in collaboration with Nagi Biosciences SA, the study demonstrates significant age-reversal effects in aging model organisms treated with Telomir-1, effectively turning back the biological clock.

Telo Genomics Assessing MRD Status in TELO-DMRD Study
newsfilecorp.com10 September 2024 Sentiment: POSITIVE

Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it is evaluating its minimal residual disease (MRD) biomarker assay technologies in multiple myeloma (MM) patients as a part of the TELO-DMRD clinical validation study. Telo's MRD assays are being evaluated utilizing Adaptive Biotechnologies' clonoSEQ assay technology as a component of Telo's ongoing MRD clinical trial, TELO-DMRD (NCT05530096), being conducted with McGill University, Montreal, Canada.

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1
globenewswire.com30 May 2024 Sentiment: NEUTRAL

Commences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study to evaluate the safety of Telomir-1 on geriatric canines

IPO Update: Telomir Pharmaceuticals Proposes IPO Terms
Seeking Alpha16 December 2023 Sentiment: NEGATIVE

Telomir Pharmaceuticals plans to raise $7 million through an IPO to fund its development of treatments for age-related inflammatory conditions. The company's lead candidate, TELOMIR-1, has the potential to act as an Interleukin-17 inhibitor for conditions such as hemochromatosis and osteoarthritis. Given TELO's thin capitalization, high valuation expectations and early stage of development, my opinion on the IPO is to Sell [Avoid].

What type of business is Telomir Pharmaceuticals Common Stock?

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

What sector is Telomir Pharmaceuticals Common Stock in?

Telomir Pharmaceuticals Common Stock is in the Healthcare sector

What industry is Telomir Pharmaceuticals Common Stock in?

Telomir Pharmaceuticals Common Stock is in the Biotechnology industry

What country is Telomir Pharmaceuticals Common Stock from?

Telomir Pharmaceuticals Common Stock is headquartered in United States

When did Telomir Pharmaceuticals Common Stock go public?

Telomir Pharmaceuticals Common Stock initial public offering (IPO) was on 09 April 2019

What is Telomir Pharmaceuticals Common Stock website?

https://telomirpharma.com

Is Telomir Pharmaceuticals Common Stock in the S&P 500?

No, Telomir Pharmaceuticals Common Stock is not included in the S&P 500 index

Is Telomir Pharmaceuticals Common Stock in the NASDAQ 100?

No, Telomir Pharmaceuticals Common Stock is not included in the NASDAQ 100 index

Is Telomir Pharmaceuticals Common Stock in the Dow Jones?

No, Telomir Pharmaceuticals Common Stock is not included in the Dow Jones index

When was Telomir Pharmaceuticals Common Stock the previous earnings report?

No data

When does Telomir Pharmaceuticals Common Stock earnings report?

The next expected earnings date for Telomir Pharmaceuticals Common Stock is 29 November 2024